These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26632476)

  • 1. [Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma].
    Zhu H; Xu W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):972-6. PubMed ID: 26632476
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Gordon MJ; Lewis LD; Brown JR; Danilov AV
    Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J
    Leuk Lymphoma; 2016 Sep; 57(9):2204-7. PubMed ID: 26699798
    [No Abstract]   [Full Text] [Related]  

  • 6. Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
    Vidal L; Gurion R; Shargian L; Dreyling M; Gafter-Gvili A
    Br J Haematol; 2019 Jul; 186(2):234-242. PubMed ID: 30980398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Tisi MC; Paolini R; Piazza F; Ravelli E; Tecchio C; Sartori R; Famengo B; D'Amore ESG; Carli G; Perbellini O; Di Bona E; Ruggeri M; Visco C
    Am J Hematol; 2018 Dec; 93(12):E386-E389. PubMed ID: 30184246
    [No Abstract]   [Full Text] [Related]  

  • 8. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Olszewski AJ; Reagan JL; Castillo JJ
    Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

  • 10. Bendamustine: role and evidence in lymphoma therapy, an overview.
    Derenzini E; Zinzani PL; Cheson BD
    Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Khodarahmi I; Ghesani N
    Blood; 2017 Aug; 130(9):1174. PubMed ID: 28860327
    [No Abstract]   [Full Text] [Related]  

  • 12. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
    Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
    [No Abstract]   [Full Text] [Related]  

  • 14. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.
    Prusila REI; Haapasaari KM; Marin K; Pollari M; Soini Y; Vornanen M; Karjalainen-Lindsberg ML; Turpeenniemi-Hujanen T; Kuittinen O
    Acta Oncol; 2018 Sep; 57(9):1265-1267. PubMed ID: 29537344
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
    Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
    Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the Hodgkin's Lymphoma Variant of Richter's Transformation.
    Zahid MF
    J Coll Physicians Surg Pak; 2016 Apr; 26(4):344-5. PubMed ID: 27097715
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 19. Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine.
    Iliff A; Divine C; Diaz F; Aljitawi O; Abhayankar S; McGuirk J; Ganguly S
    Leuk Lymphoma; 2016 May; 57(5):1189-90. PubMed ID: 26294340
    [No Abstract]   [Full Text] [Related]  

  • 20. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.